Key Highlights
- $9M BARDA Partnership to Advance Point-of-Care Filovirus Testing
Aptitude Medical Systems secures $9 million from BARDA to develop the Metrix Filovirus Panel, targeting rapid detection and differentiation of Ebolavirus and Marburgvirus species directly at the point of care. - Metrix Platform Extends to Blood Diagnostics—Results in 30 Minutes
Aptitude’s next-gen Metrix® molecular diagnostics platform, now validated for blood samples, promises portable, lab-quality testing in remote settings with 30-minute results—drastically reducing time to intervention during outbreaks. - Mission to Democratize Global Infectious Disease Surveillance
By simplifying and decentralizing molecular diagnostics, Aptitude expands Metrix’s reach beyond respiratory infections, empowering healthcare systems for rapid outbreak containment and improved global health security.
BARDA Partnership Accelerates Filovirus Diagnostic Innovation
Aptitude’s second collaboration with BARDA brings $9 million in new federal funding to develop the Metrix Filovirus Panel—building on a prior partnership valued up to $61.9 million. This initiative directly addresses the urgent need for field-deployable diagnostics for deadly pathogens, leveraging BARDA’s strategic focus on outbreak preparedness and public health resilience.
Metrix Platform: Blood-Based Molecular Testing Goes Portable
The Metrix Filovirus Panel marks the first time Aptitude’s Metrix® platform will deliver molecular diagnostics from venous or fingerstick blood samples, providing results in 30 minutes or less. Its small, portable design is tailored for outbreak sites, enabling timely, actionable decisions far from centralized laboratories.
Boosting Early Outbreak Response and Decentralized Care
Fast, decentralized diagnostics are vital against highly transmissible and lethal viruses like Ebola and Marburg. This new panel supports immediate patient triage and targeted containment efforts—breaking the bottleneck of slow, centralized testing and reducing the risks of delayed treatment and widespread transmission.
Aptitude’s Broader Mission: Lab-Quality Diagnostics for All
This latest breakthrough continues Aptitude’s mission to democratize diagnostic access, extending its validated platform beyond COVID-19 and respiratory illnesses. Efficient, affordable, and easy-to-use molecular testing empowers global health systems and communities to address current and future outbreaks with speed and precision.
About Aptitude
Aptitude is a pioneering deep-tech healthcare company revolutionizing infectious disease detection and treatment. Its mission is to democratize diagnostics by providing actionable, lab-quality results anywhere, in minutes. With a pipeline spanning infectious and wellness conditions—and market-cleared Metrix® COVID-19 and COVID/Flu tests—Aptitude is redefining the standard for point-of-care molecular diagnostics.
By
